<DOC>
	<DOCNO>NCT01463215</DOCNO>
	<brief_summary>Ambroxol expect improve sign symptom patient Type I Gaucher Disease .</brief_summary>
	<brief_title>Clinical Trial Ambroxol Patients With Type I Gaucher Disease</brief_title>
	<detailed_description>This Open-Label , Dose Escalation 2 Dose Levels , Proof-of-Concept Clinical Trial Ambroxol Treatment Patients Type I Gaucher Disease . This study randomize clinical trial involve 20 evaluable patient affect Type 1 Gaucher disease responsive Ambroxol vitro . There 2 treatment group , involve 2 dose level Ambroxol ( 187.5 225 mg/day ) , give daily PO 2 month group . The 187.5-mg/day dose level test first . If significant adverse event , define &gt; Grade 3 toxicity accord late version National Cancer Institute ( NCI ) Common Toxicity Criteria ( CTC ) , 225-mg/day dose level test .</detailed_description>
	<mesh_term>Gaucher Disease</mesh_term>
	<mesh_term>Ambroxol</mesh_term>
	<criteria>Biochemically genetically confirm diagnosis Gaucher disease cause Î²glucocerebrosidase deficiency result mutation GBA gene , show respond Ambroxol accord vitro screening assay . Must 16 year age old time study initiation . With intact , enlarge spleen . A hemoglobin level least 10 g/L . Able understand cooperate requirement study protocol . Mentally competent , ability understand willingness sign inform consent form . Able travel participate study site . Women childbearing potential must use accepted contraceptive method , must negative serum urine pregnancy test within one week prior treatment initiation . An additional pregnancy test perform , result obtain , prior administration first dose Ambroxol . Fertile men must practice effective contraceptive method study period , unless documentation infertility exist . Body weight &gt; 40 kg ( 88 lb ) . Receipt form glucocerebrosidase &lt; &lt; 4 week prior study initiation . Total splenectomy . Serious medical illness , significant cardiac disease , chronic bronchitis , emphysema , cystic fibrosis , well disorder cause ventilation perfusion mismatch . Substance abuse . Any complex disease may confound treatment assessment . Pregnant woman , woman childbearing potential use reliable mean contraception . Lactating female potential adverse reaction nurse infant . Fertile men unwilling practice contraceptive method study period . Unwilling unable follow protocol requirement . Known hypersensitivity reaction , intolerance adverse reaction Ambroxol inactive ingredient . Evidence systemic infection , serious infection within past month . Known HIV infection . Known hepatitis B hepatitis C. Patients history convulsive disorder . Patients receive investigational treatment indication within past 4 week prior initiation Ambroxol treatment . A history cancer type . Patients receive immunotherapy type within past 4 week prior study initiation . Any condition abnormality may , opinion investigator , compromise safety patient .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Ambroxol</keyword>
	<keyword>Type I Gaucher Disease</keyword>
</DOC>